Kukje Pharma Co., Ltd.

KSE 002720.KS

Kukje Pharma Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending December 31, 2023: USD 2.00 M

Kukje Pharma Co., Ltd. Net Cash Used Provided By Financing Activities is USD 2.00 M for the year ending December 31, 2023, a 133.95% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

Kukje Pharma Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending December 31, 2022 was USD -5.90 M, a -189.82% change year over year.
Kukje Pharma Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending December 31, 2021 was USD -2.04 M, a -456.80% change year over year.
Kukje Pharma Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending December 31, 2020 was USD 570.95 K, a -87.58% change year over year.
Kukje Pharma Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending December 31, 2019 was USD 4.60 M, a 190.50% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

KSE: 002720.KS

Kukje Pharma Co., Ltd.

CEO	Tae-hoon Nam
IPO Date	Sept. 29, 2005
Location	South Korea
Headquarters	96-8, Yatap-ro
Employees	247
Sector	Healthcare
Industries Pharmaceuticals Cleaning Supplies Cosmetics Drugstores & Retail Pharmacies Eyewear Personal Care

Description

Kukje Pharma Co., Ltd. engages in manufacturing, importing, exporting, selling, and distributing pharmaceutical products. The company offers pharmaceutical products, including ETC and OTC products, raw materials, intermediates, and side chain products, as well as cosmetics and health care products. Its products include cephalosporins, quinolones, tetracycline, aminoglycosides, macrolides, ophthalmic, antifungal and antiviral agents, ophthalmic agents, adrenal corticosteroids, CNS and osteoporotic agents, antihistamines, NSAIDS and other analgesics, gastrointestinal and cardiovascular agents, antidiabetics, genitourinary and respiratory agents, and other ETC products. The company was founded in 1959 and is headquartered in Seongnam, South Korea.

Key trends

Past 5 years